Table 1 Papers included in this meta-analysis of weight change during chemotherapy for women with early stage breast cancer
From: Weight change during chemotherapy in breast cancer patients: a meta-analysis
First author, year of publication | Year of enrolment | Study design | Sample (sample size, key characteristics) | Type of chemotherapy | Follow-up | Mean weight gain in kg (se) in total group | Subgroup analysis Mean weight gain in kg (se) |
|---|---|---|---|---|---|---|---|
Foltz, 1985 [32] | UN | Prospective | n = 34, pre- and postmenopausal, stage II, adjuvant | CMF | pretreatment - 6 months | 2.99 (2.85) |  |
Heasman, 1985 [33] | 1975–1981 | Retrospective Chart review | n = 237, pre- and postmenopausal, adjuvant | n = 46 single agent chemotherapy n = 112 CMF n = 79 CMF + prednisone | Pre – posttreatment | 4.32 (0.23) | Single agent: 2.72 (0.33) CMF: 3.65 (0.32) CMF + prednisone: 6.20 (0.4) |
Huntington, 1985 [34] | UN | Retrospective Chart review | n = 29, pre- and postmenopausal, adjuvant | n = 18 CMF n = 11 CMFVP | Pre – posttreatment | 4.58 (0.58) | Premenopausal: 7.67 (0.89) Postmenopausal: 2.63 (0.72) Perimenopausal: 4.76 (0.12) |
Goodwin, 1988 [35] | 1960–1984 | Retrospective Chart review | n = 193, pre- and postmenopausal, adjuvant | n = 113 CMF n = 80 CMF + prednison | Pretreatment - 12 months |  | CMF: 2.51 (0.24) CMF+ prednison 5.55 (0.62) |
Demark–Wahnefried, 1997 [13] | 1993–1995 | Prospective | n = 18, premenopausal, adjuvant | n = 9 AC n = 5 CAF n = 1 CMF n = 1 CMF + leucovorin n = 1 A + CMF n = 1 AC + leucovorin | Pre- posttreatment | 0 (3.48) |  |
Aslani, 1999 [36] | UN | Prospective | n = 25, pre- and postmenopausal, adjuvant | CMF | Pre- posttreatment | 2.35 (0.62) |  |
Goodwin, 1999 [37] | 1989–1996 | Prospective | n = 176, pre- and postmenopausal, adjuvant | n = 128 non-antracyclines n = 48 antracyclines | Pretreatment - 12 months | 2.5 (0.36) |  |
Kutynec, 1999 | UN | Prospective | n = 8, pre- and perimenopausal, adjuvant | AC | Pre- posttreatment | 0 (2.85) |  |
Demark-Wahnefried, 2001 [12] | 1995–1999 | Prospective | n = 36, premenopausal, adjuvant | n = 17 doxorubicin regimens n = 12 doxorubicin regimens + tamoxifen, n = 6 CMF n = 1 CMF + tamoxifen | Pretreatment - 6 months | 2.2 (0.37) |  |
McInnes, 2001 [1] | UN | Retrospective Chart review | n = 44, pre- and postmenopausal, adjuvant | n = 19 CMF - oral n = 6 CMF - iv n = 2 CAF - oral n = 9 CAF - iv n = 8 Other | Pretreatment - 6 months | 3.4 (0.33) |  |
Del Rio, 2002 [39] | UN | Prospective | n = 30, premenopausal, adjuvant | CMF | Pretreatment - 6 months | 2.8 (0.56) |  |
Lankester, 2002 [40] | 1998 | Retrospective Chart review | n = 100, pre- and postmenopausal, adjuvant + neo-adjuvant | n = 69 FEC n = 31 CMF | Pretreatment-before last cycle | 3.68 (0.4) |  |
Freedman, 2004 [7] | 1999–2001 | Prospective | n = 20, pre- and posttreatment, adjuvant | n = 8 AC n = 10 AC + paclitaxel n = 2 AC + docetaxel | Pre- posttreatment | −0.83 (0.81) |  |
Harvie, 2004 [18] | UN | Prospective | n = 17, pre- and postmenopausal, adjuvant | n = 12 FEC n = 5 CMF | Pre- posttreatment | 3.3 (1.02) |  |
Ingram, 2004 [6] | UN | Prospective | n = 76, premenopausal, adjuvant | n = 39 AC n = 33 CEF n = 4 CMF | Pre- posttreatment | 1.4 (0.39) | AC: 1 (0.34) CEF: 1.5 (0.77) CMF: 5 (1.8) |
Kumar, 2004 [41] | UN | Prospective | n = 170, pre- and postmenopausal, adjuvant | n = 107 CA n = 45 CA + taxol n = 17 other | Pre- posttreatment | 0.4 (1.13) |  |
Campbell, 2007 [19] | 2001–2003 | Prospective | n = 10, pre- and postmenopausal, adjuavnt | n = 5 CEF n = 5 AC | Pre- posttreatment | 1.98 (5.06) |  |
Courneya, 2007 [42] | 2003–2005 | Trial | n = 82 pre- and postmenopausal, adjuvant | n = 23 FE100C n = 20 AC n = 8 CE120F n = 3 other non-taxanen n = 10 TAC n = 14 AC-Taxanen n = 4 other taxanen | Pre- posttreatment | 1.2 (1.71) |  |
Makari-Judson, 2007 [20] | 1997–2002 | Retrospective Chart review | n = 123, pre- and postmenopausal, adjuvant | AC, AC + taxanen, CAF, Doxorubicin + CMF, CMF or MF n = 109 antracycline containing CT n = 14 non antracycline | Pretreatment - 12 months | 2.6 (0.57) |  |
Heideman, 2009 [8] | 1974–2006 | Retrospective | n = 31 (CT only), pre- and postmenopausal, adjuvant | AC, EC, CMF, FAC, FEC, other incl herceptin | Pretreatment - 12 months | 2.2 (2.07) |  |
Heideman, 2009 [8] | 1974–2006 | Retrospective | n = 67 (Combined), pre- and postmenopausal, adjuvant | AC, EC, CMF, FAC, FEC, other incl herceptin | Pretreatment - 12 months | 2.6 (1.69) |  |
Biglia, 2010 | 2007–2008 | Prospective | n = 34, premenopausal, adjuvant | n = 17 FEC n = 17 FEC + taxotere | After surgery-end CT | 2.07 (0.45) |  |
Tredan, 2010 [44] | 2004–2006 | Prospective | n = 242, pre- and postmenopausal, adjuvant | n = 110 anthracycline without taxane n = 156 anthracycline + taxane n = 2 taxane (1%)n = 4 missing data | Pretreatment – 6 months after CT | 0.7 (0.23) | Premenopausal: 1.2 (0.31) Postmenopausal: 0.2 (0.33) |
Basaran, 2011 [45] | 2003–2004 | Retrospective Chart review | n = 171, pre- and postmenopausal, adjuvant | N = 111 Antracycline based N = 55 Antracycline/taxane N = 5 No CT | Pre- posttreatment | 1.7 (0.94) |  |
Jeon, 2014 [46] | 2005–2010 | Retrospective Chart review | N = 108, pre- and postmenopausal, adjuvant | TAC | Pre- posttreatment | 3.64 (3.7) |  |
Winkels, 2014 [47] | 2001–2010 | Retrospective Chart review | N = 483, re and postmenopausal | n = 289 antracycline based n = 170 antracycline + taxane n = 10 CMF n = 14 other | Pre-posttreatment | 1.2 (0.25) |  |